PALO ALTO and SANTA ROSA, Calif., Feb. 4 (HSMN NewsFeed) -- CV Therapeutics, Inc. (Nasdaq: CVTX ) and Medlogics Device Corporation announced today that the companies have entered into an agreement under which Medlogics has licensed CV Therapeutics' proprietary biopolymer stent coating technology to develop a drug eluting stent (DES). CV Therapeutics received Medlogics stock and is entitled to development milestone payments, royalties and other potential payments on future sales of any products incorporating the technology.
Medlogics recently received a CE Mark from European regulatory authorities for its Cobalt Super Alloy (COBRA) stent and expects to launch the stent in Europe in the first quarter of 2008. Medlogics expects to utilize CV Therapeutics' biopolymer stent coating technology to develop a next- generation DES based on the COBRA stent platform.
full article >> http://salesandmarketingnetwork.com/news_release.php?ID=2023071
Tuesday, February 5, 2008
CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment